NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs
FORT WORTH, Texas–NanOlogy LLC, a clinical-stage oncology company, announces a presentation of clinical research involving its large surface area microparticle (LSAM) investigational drugs at DDW 2023 in May and publication at ASCO Annual Meeting in June.
The DDW poster entitled “Intracystic Injection of Large Surface Area Microparticle Paclitaxel (LSAM-PTX) for Chemoablation of Intraductal Papillary Mucinous Neoplasms: Insights from an Expanded Access Protocol,” was presented by the research team of Somashekar Krishna, MD of The Ohio State University Wexner Medical Center. Dr. Krishna, a global expert in the treatment of mucinous pancreatic neoplasms, was a clinical investigator and author of published results (Endosc Int Open 2022) of an earlier clinical trial of intracystic LSAM-PTX in pancreatic cysts. The expanded access protocol prospectively evaluated safety and response of six subjects from the trial who received additional doses of LSAM-PTX. “In this protocol, intracystic LSAM-PTX was safe and resulted in cyst volume and surface area reduction, morphological changes, and loss of pathogenic mutations,” said Dr. Krishna. “Further clinical research is warranted particularly in nonsurgical high-risk cyst patients because of the lack of approved treatments to decrease risk for progression to pancreatic cancer.”
The ASCO abstract (e15187) entitled “Safety of locally administered large surface area microparticle paclitaxel (LSAM-PTX) and docetaxel (LSAM-DTX) in combination with standard of care therapies,” was accepted for publication in the ASCO annual meeting library. The abstract, authored by Shelagh Verco, PhD, Holly Maulhardt, and other NanOlogy researchers, reviews the safety of both investigational drugs in combination with SOC therapies including various chemotherapies, immune checkpoint inhibitors, and/or radiation across 7 clinical trials totaling 156 patients. The review concluded that local treatment of solid tumors with LSAM-PTX or LSAM-DTX has the potential to overcome some limitations of SOC therapies by increasing tumor dwell time and reducing systemic toxicities which are often exacerbated in combinatorial treatment regimens.
NanOlogy, LLC (www.nanology.us) is a private clinical-stage oncology company formed in 2015 to improve the treatment of solid tumors based on a proprietary particle engineering technology platform for intratumoral drug therapy to maximize drug in tumor and minimize systemic toxicity. Taxane drug particles are covered by composition of matter patents issued in the US (US 9,814,685, US 10,507,195, US 10,993,927, and US 11,123,322), and other major jurisdictions worldwide, including Canada, Europe, Japan, China, South Korea, and Australia valid through June 2036. The composition patents form the foundation of an extensive intellectual property portfolio of over 130 issued patents protecting NanOlogy investigational drugs, formulations, methods, and technology. NanOlogy clinical programs have advanced locally administered LSAM investigational drugs in multiple solid tumors including pancreas, lung, bladder, peritoneal, ovarian, prostate, and dermal cancers.
This announcement contains forward-looking statements defined in the Private Securities Litigation Reform Act of 1995, as amended, including statements about our product development, business, and other activities. Such statements are subject to risks and uncertainties inherent in any pharmaceutical development program which may cause actual results to differ materially due to developmental, clinical, regulatory, market, competitive, technological, or other factors. All forward-looking statements are made as of the date of this announcement and the company disclaims any intent or obligation to update these statements. NanOlogy investigational drugs have not been proven safe and effective as required by U.S. FDA and have not been approved by FDA or any other jurisdiction for commercial distribution. NanOlogy is a trademark of NanOlogy LLC.
Opus Biotech Communications